Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Enhertu Hits PIII Primary Goal in 1st-Line HER2-Mutant NSCLC
Daiichi Sankyo said on August 17 that Enhertu (trastuzumab deruxtecan) met the primary endpoint in the global PIII DESTINY-Lung04 trial for the first-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC). In the…
To read the full story
Related Article
- Daiichi Sankyo Kicks Off PIII for Enhertu in Frontline NSCLC
December 27, 2021
BUSINESS
- 3D Seeks Injunction against Toho’s Poison Pill
August 18, 2026
- Enhertu Hits PIII Primary Goal in 1st-Line HER2-Mutant NSCLC
August 18, 2026
- Enhertu Combo Scores China Nod in 1st-Line HER2 Breast Cancer
August 18, 2026
- Santen Releases Glaucoma Drug Rhopressa in Japan
August 18, 2026
- Yaz AGs Now Available in Japan, Hisamitsu Handling Distribution
August 18, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…